Representatives of Bausch & Lomb
, Warburg, Goldman Sachs, Abbott, Sanofi, Johnson & Johnson, Evercore, Morgan Stanley, Merck and Pfizer would not comment when reached by Bloomberg.Target: Bausch & Lomb
IncBuyer: Sanofi SA , Johnson & Johnson , Pfizer Inc , Abbott Laboratories , Merck & Company IncVendor: Warburg Pincus LLCType: Corporate acquisitionStatus: SpeculationBuyer advisor: Morgan Stanley , Evercore Partners Inc Comment: Deal size speculated at USD10bn.
"The advancements we've made during this busy period have expanded our portfolio of products to help meet the growing health care and lifestyle demands of consumers," says Joseph Gordon, president of consumer health and vision care at Bausch + Lomb
Pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSX:VRX) reported on Tuesday the completion of the acquisition of Bausch + Lomb
"Bausch + Lomb
's world-renowned brand, comprehensive portfolio of leading eye care products and promising late stage pipeline are an ideal strategic fit for our current ophthalmology business, and we are strongly committed to continuing to build a sustainable eye health business," says Valeant chairman and chief executive officer J.
Bausch & Lomb
has been in business since 1853 and delivers its products to customers in over 100 countries.
Mr van Zyl joined Bausch & Lomb
in 2009, serving as vice president, EMEA, for the company's pharmaceuticals business.
Available this month, PreserVision AREDS 2 Formula was created to meet the growing consumer preference for chewable tablets, Bausch + Lomb
Now, Bausch + Lomb
has decided to exercise its right to take full control of the venture and expects to complete the transaction at the end of January 2013.
Bausch + Lomb
, a global eye health company, on Wednesday announced that it has completed its acquisition of ISTA Pharmaceuticals Inc, a pharmaceutical company.
Release date- 31072019 - BRIDGEWATER - Bausch + Lomb
, a leading global eye health company, today announced that it has initiated the first in a series of U.S.